KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Charles River Laboratories International (CRL) Invested Capital (2016 - 2025)

Historic Invested Capital for Charles River Laboratories International (CRL) over the last 17 years, with Q3 2025 value amounting to $3.4 billion.

  • Charles River Laboratories International's Invested Capital fell 994.95% to $3.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 billion, marking a year-over-year decrease of 994.95%. This contributed to the annual value of $3.5 billion for FY2024, which is 375.66% down from last year.
  • As of Q3 2025, Charles River Laboratories International's Invested Capital stood at $3.4 billion, which was down 994.95% from $3.4 billion recorded in Q2 2025.
  • Charles River Laboratories International's 5-year Invested Capital high stood at $3.8 billion for Q3 2024, and its period low was $2.2 billion during Q1 2021.
  • Over the past 5 years, Charles River Laboratories International's median Invested Capital value was $3.2 billion (recorded in 2025), while the average stood at $3.1 billion.
  • As far as peak fluctuations go, Charles River Laboratories International's Invested Capital soared by 2863.99% in 2021, and later plummeted by 1223.29% in 2025.
  • Quarter analysis of 5 years shows Charles River Laboratories International's Invested Capital stood at $2.5 billion in 2021, then rose by 17.28% to $3.0 billion in 2022, then grew by 20.84% to $3.6 billion in 2023, then dropped by 3.76% to $3.5 billion in 2024, then dropped by 1.63% to $3.4 billion in 2025.
  • Its Invested Capital stands at $3.4 billion for Q3 2025, versus $3.4 billion for Q2 2025 and $3.2 billion for Q1 2025.